rs727504111

Variant summary

Our verdict is Pathogenic. The variant received 10 ACMG points: 10P and 0B. PM1PM2PM5PP3_Strong

The NM_145239.3(PRRT2):​c.916G>A​(p.Ala306Thr) variant causes a missense change. The variant allele was found at a frequency of 0.00000657 in 152,118 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. A306P) has been classified as Likely pathogenic.

Frequency

Genomes: 𝑓 0.0000066 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0 ( 0 hom. )
Failed GnomAD Quality Control

Consequence

PRRT2
NM_145239.3 missense

Scores

12
6
1

Clinical Significance

Uncertain significance criteria provided, multiple submitters, no conflicts U:3

Conservation

PhyloP100: 6.01

Publications

9 publications found
Variant links:
Genes affected
PRRT2 (HGNC:30500): (proline rich transmembrane protein 2) This gene encodes a transmembrane protein containing a proline-rich domain in its N-terminal half. Studies in mice suggest that it is predominantly expressed in brain and spinal cord in embryonic and postnatal stages. Mutations in this gene are associated with episodic kinesigenic dyskinesia-1. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jan 2012]
MVP-DT (HGNC:56029): (MVP divergent transcript)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Pathogenic. The variant received 10 ACMG points.

PM1
In a hotspot region, there are 7 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 2 benign, 17 uncertain in NM_145239.3
PM2
Very rare variant in population databases, with high coverage;
PM5
Other missense variant is known to change same aminoacid residue: Variant chr16-29814369-G-C is described in ClinVar as Conflicting_classifications_of_pathogenicity. ClinVar VariationId is 536487.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.954

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
PRRT2NM_145239.3 linkc.916G>A p.Ala306Thr missense_variant Exon 3 of 4 ENST00000358758.12 NP_660282.2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
PRRT2ENST00000358758.12 linkc.916G>A p.Ala306Thr missense_variant Exon 3 of 4 1 NM_145239.3 ENSP00000351608.7
ENSG00000280893ENST00000609618.2 linkn.905G>A non_coding_transcript_exon_variant Exon 3 of 6 5 ENSP00000476774.2

Frequencies

GnomAD3 genomes
AF:
0.00000657
AC:
1
AN:
152118
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000147
Gnomad OTH
AF:
0.00
GnomAD4 exome
Data not reliable, filtered out with message: AC0
AF:
0.00
AC:
0
AN:
1457098
Hom.:
0
Cov.:
35
AF XY:
0.00
AC XY:
0
AN XY:
724958
African (AFR)
AF:
0.00
AC:
0
AN:
33438
American (AMR)
AF:
0.00
AC:
0
AN:
44464
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
25994
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39690
South Asian (SAS)
AF:
0.00
AC:
0
AN:
86014
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
50482
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5650
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
1111116
Other (OTH)
AF:
0.00
AC:
0
AN:
60250
GnomAD4 genome
AF:
0.00000657
AC:
1
AN:
152118
Hom.:
0
Cov.:
32
AF XY:
0.00
AC XY:
0
AN XY:
74306
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
41394
American (AMR)
AF:
0.00
AC:
0
AN:
15286
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3472
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5172
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4832
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10618
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
316
European-Non Finnish (NFE)
AF:
0.0000147
AC:
1
AN:
68022
Other (OTH)
AF:
0.00
AC:
0
AN:
2094
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.475
Heterozygous variant carriers
0
0
1
1
2
2
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Uncertain:2
Dec 10, 2013
Eurofins Ntd Llc (ga)
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Feb 10, 2025
GeneDx
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Reported in a patient and mother with benign familial infantile seizures in published literature (PMID: 23077026); Published functional studies are inconclusive as to whether the variant alters protein function and structure (PMID: 31124310, 30980674); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 30980674, 31124310, 31193310, 25502464, 34478843, 23077026) -

Inborn genetic diseases Uncertain:1
Jul 23, 2019
Ambry Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The p.A306T variant (also known as c.916G>A), located in coding exon 2 of the PRRT2 gene, results from a G to A substitution at nucleotide position 916. The alanine at codon 306 is replaced by threonine, an amino acid with similar properties. This variant was reported in an individual with benign familial infantile seizures and also in her similarly affected mother (Marini C et al. Neurology, 2012 Nov;79:2109-14). In addition, this variant was detected in a compound heterozygous proband who had epilepsy with status epilepticus, paroxysmal dyskinesia and episodic ataxia, and also had a PRRT2 c.649dupC mutation; the p.A306T variant was detected in his father, who had history of aphasia and episodes of confusion (El Achkar CM et al. Epilepsy Behav Case Rep, 2019 Feb;11:125-128). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.98
BayesDel_addAF
Pathogenic
0.56
D
BayesDel_noAF
Pathogenic
0.56
CADD
Pathogenic
33
DANN
Pathogenic
1.0
DEOGEN2
Uncertain
0.79
D;T;.;D;D;D
Eigen
Pathogenic
0.85
Eigen_PC
Pathogenic
0.72
FATHMM_MKL
Uncertain
0.95
D
LIST_S2
Uncertain
0.91
.;D;D;.;.;D
M_CAP
Pathogenic
0.60
D
MetaRNN
Pathogenic
0.95
D;D;D;D;D;D
MetaSVM
Pathogenic
1.1
D
MutationAssessor
Pathogenic
3.6
H;.;H;H;H;H
PhyloP100
6.0
PrimateAI
Uncertain
0.65
T
PROVEAN
Uncertain
-3.2
D;.;D;.;.;.
REVEL
Pathogenic
0.97
Sift
Uncertain
0.0020
D;.;D;.;.;.
Sift4G
Pathogenic
0.0
D;.;D;.;D;.
Polyphen
1.0
D;.;D;D;D;D
Vest4
0.96
MutPred
0.78
Gain of phosphorylation at A306 (P = 0.1076);.;Gain of phosphorylation at A306 (P = 0.1076);Gain of phosphorylation at A306 (P = 0.1076);Gain of phosphorylation at A306 (P = 0.1076);Gain of phosphorylation at A306 (P = 0.1076);
MVP
1.0
MPC
0.86
ClinPred
1.0
D
GERP RS
3.8
PromoterAI
-0.066
Neutral
Varity_R
0.90
gMVP
0.99
Mutation Taster
=10/90
disease causing

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.040
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs727504111; hg19: chr16-29825690; API